Isarna Therapeutics is attracting an international team of scientists, researchers, and clinicians who are leading experts in the fields of TGF-β, translational medicine and ophthalmology.
Philip J Rosenfeld, MD, Ph.D
Professor, Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, USA
A profound specialist in vitreoretinal diseases, Professor Philip J. Rosenfeld was instrumental in developing anti-VEGF therapy for wet AMD and continues to support developing novel therapies for this condition. His work validated that a small amount of the drug Avastin, which was approved by the FDA for the treatment of metastatic colorectal cancer, could be injected directly into the eye to help prevent blindness. He determined that the off-label use of this therapy was effective in stopping blood vessels from leaking, growing and damaging the retina in the eye.